India's reliance on foreign regulatory approvals (US, UK, EU, etc.) for waiving clinical trials of medical devices — discuss the rationale, benefits, and risks of such regulatory equivalence mechanisms.

Rule 63 of the Medical Devices Rules, 2017 allows waiver of clinical investigation for devices already approved in "stringent regulatory jurisdictions" — the USA, UK, Australia, Canada and Japan, with the European Union proposed to be added [1]. Such reliance accelerates access, but its worth depends on the safeguards attached to it.

Rationale for regulatory equivalence

• Capacity constraint: devices received a dedicated framework only in 2017, under the Drugs and Cosmetics Act, 1940; CDSCO's evaluator strength is thin relative to the thousands of device categories it must assess [1].
• Accepted global practice: WHO treats reliance — giving significant weight to a trusted regulator's assessment — as good regulatory practice, not a shortcut [3].
• Import dependence: India still imports a large share of high-end devices; repeating trials already completed abroad duplicates evidence [4].
• Ease of doing business: the same reform track removes duplicative sterilisation loan licences and rationalises licensing timelines [2].

Benefits

• Faster availability of devices having no predicate in India, especially critical-care and diagnostic-imaging equipment.
• Lower compliance cost and time-to-market, aiding MSMEs and start-ups without trial budgets [2].
• Harmonisation signals predictability to investors, supporting the National Medical Devices Policy, 2023 [4].
• Frees scarce regulatory bandwidth for high-risk Class C and D devices and for factory inspections.

Risks

• Safety is not transferable: the foreign-approved DePuy ASR hip implant failed, forcing the Health Ministry to approve a compensation formula for affected Indian patients [5].
• Population differences: anthropometric, genetic and climatic variation may alter device performance, and no Indian-population data is generated.
• Regulatory dependence: India's decisions then track foreign recalls, weakening indigenous evaluation and clinical-trial ecosystems.
• Weak back-end: reliance shifts the burden onto post-market surveillance and materiovigilance; traceability tools like the proposed printing of the sterilisation licence number on labels are necessary but not sufficient [2].

Regulatory equivalence is best treated as a capacity multiplier rather than a substitute for domestic regulation. Waivers should be paired with mandatory post-marketing surveillance, implant registries and phased strengthening of CDSCO, so that the ease-of-doing-business gain is matched by patient safety — precisely the balance the Medical Devices Rules were framed to strike.